Boardroom Alpha
8-K primary document
AMST · Current Report (Form 8-K) · Filed October 30, 2025

Amesite Inc8-K exhibit

ea026312701ex99-1_amesite.htm

Exhibit 99.1

 

Amesite Announces 69% QoQ Revenue Increase in Q2 2026 and Product Plans for Coming Months

 

Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute Healthcare

 

DETROIT, October 30, 2025 (GLOBE NEWSWIRE) – Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its pathway to offer the first AI-powered electronic medical record (EMR) by 2026 in a shareholder update made available yesterday on its website. As part of the shareholder update, Amesite Founder & CEO, Dr. Ann Marie Sastry discussed:

 

Summary of FY 2025 10-K and Q1 2026 10-Q: Financial performance was described in the context of methodical execution of platform capabilities demanded by customers.

 

Excellent Product Reviews: Customer feedback was described, underscoring high satisfaction and increased adoption in post-acute healthcare segments.

 

Efficient Technology Innovation: Rapid deployment of Amesite's proprietary AI technology was described, crediting the AI-forward infrastructure used at the inception of the NurseMagicTM product family.

 

Upcoming Product Plans: Amesite announced the planned launch of what it believes is the industry’s first AI-powered EMR platform for post-acute care, aiming to deliver operational efficiency for the fastest-growing healthcare segments.

 

“Our team’s focus on operational discipline has enabled us to drive revenue growth while reducing operating expenses,” said Madison Bush, Director of Corporate Operations. “We are focused on delivering increased value to our shareholders by practicing what we preach: using AI-powered process optimization that continuously increases our business efficiency. Importantly, our customer engagement has accelerated since Q12026, with an average of 6,500 daily views of our platform explainer video and 28,000 daily website visitors.”

 

“Our increased revenue, of 82% and 69% QoQ for the last two quarters, reflects the strong demand from our customers for NurseMagicTM’s AI-powered platform support,” added Brandon Owens, VP of Sales. “With a strong technology foundation, and relationships built through delivery of value, we believe that we will grow our business with existing customers and also onboard new, larger clients because of our differentiation in technology.”

 

“The only way to solve the urgent need to increase the efficiency of delivery of U.S. healthcare, while also improving the quality of care, is through innovation. AI will play the most important role in this transition. By methodically rolling out capabilities and services on our proprietary, AI-powered NurseMagicTM platform, we are working to meet the strong demand for end-to-end, AI-enhanced platform support for post-acute care,” said Dr. Ann Marie Sastry, Founder & CEO.

 

About Amesite Inc.

 

Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines healthcare documentation, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.

 

Forward-Looking Statements

 

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations

 

ir@amesite.com

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer